Revumenib

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 103 publications

Menin inhibition impairs metastatic colonization of Ewing sarcoma.

Menin inhibition impairs metastatic colonization of Ewing sarcoma.

Journal: JCI insight
Published: September 03, 2026

Erratum: All-Oral Combination of Revumenib, Decitabine, and Venetoclax for Relapsed or Refractory AML (SAVE).

Erratum: All-Oral Combination of Revumenib, Decitabine, and Venetoclax for Relapsed or Refractory AML (SAVE).

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: July 23, 2026

Oral Regimens for AML Make Strides.

Oral Regimens for AML Make Strides.

Journal: Cancer discovery
Published: June 27, 2026

Revumenib-Induced QTc Prolongation Leading to Multiple Episodes of Torsades de Pointes and Ventricular Arrhythmias.

Revumenib-Induced QTc Prolongation Leading to Multiple Episodes of Torsades de Pointes and Ventricular Arrhythmias.

Journal: Ochsner journal
Published: June 18, 2026

All-Oral Combination of Revumenib, Decitabine, and Venetoclax for Relapsed or Refractory AML (SAVE).

All-Oral Combination of Revumenib, Decitabine, and Venetoclax for Relapsed or Refractory AML (SAVE).

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: June 11, 2026

Targeting the Menin-KMT2A Axis in AML: Translating Molecular Insights into Therapeutic Success.

Targeting the Menin-KMT2A Axis in AML: Translating Molecular Insights into Therapeutic Success.

Journal: Clinical lymphoma, myeloma & leukemia
Published: June 03, 2026

Emerging drug profile: menin inhibitors in NPM1-mutated and KM2A-rearranged acute myeloid leukemia.

Emerging drug profile: menin inhibitors in NPM1-mutated and KM2A-rearranged acute myeloid leukemia.

Journal: Leukemia & lymphoma
Published: May 27, 2026

Sequential Transformation of Polycythemia Vera to Myelofibrosis and KMT2A-Rearranged Acute Myeloid Leukemia Treated With Revumenib: A Rare Case of Clonal Evolution.

Sequential Transformation of Polycythemia Vera to Myelofibrosis and KMT2A-Rearranged Acute Myeloid Leukemia Treated With Revumenib: A Rare Case of Clonal Evolution.

Journal: Cureus
Published: March 17, 2026

Menin inhibition reshapes therapy in NPM1-mutated acute myeloid leukemia.

Menin inhibition reshapes therapy in NPM1-mutated acute myeloid leukemia.

Journal: Annals of translational medicine
Published: March 14, 2026

Ziftomenib (Komzifti) for acute myeloid leukemia.

Ziftomenib (Komzifti) for acute myeloid leukemia.

Journal: The Medical letter on drugs and therapeutics
Published: March 07, 2026

Two new options for NPM1-mutated relapsed, refractory acute myeloid leukemia: Researchers are looking into whether revumenib or ziftomenib can be combined with first-line standard-of-care treatment options.

Two new options for NPM1-mutated relapsed, refractory acute myeloid leukemia: Researchers are looking into whether revumenib or ziftomenib can be combined with first-line standard-of-care treatment options.

Journal: Cancer
Published: March 04, 2026

Successful Management of Lineage Switch Infant Leukemia With Revumenib and Hematopoietic Cell Transplantation.

Successful Management of Lineage Switch Infant Leukemia With Revumenib and Hematopoietic Cell Transplantation.

Journal: Pediatric blood & cancer
Published: March 04, 2026
Showing 1-12 of 103

Last Updated: 09/26/2026